Emerging cancer vaccines: the promise of genetic vectors

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Therapeutic cancer vaccination is crucial for long-term cancer control, often in combination with other treatments.
• Induction of adaptive and innate immune responses against Tumor Associated Antigens (TAAs) is key for tumor stabilization and eradication.
• Various vaccine technologies, including cell-based, protein, peptide, and heat-shock protein vaccines, have been explored.

Purpose of the Study:

• To review emerging cancer vaccine technologies, focusing on genetic vaccines.
• To discuss the challenges and requirements for developing effective cancer vaccines.
• To highlight the potential of Adenovirus (Ad)-based vectors and in vivo DNA electroporation (DNA-EP) for cancer vaccination.

Main Methods:

• Review of current literature on cancer vaccine technologies.
• Focus on genetic vaccine approaches, specifically Adenovirus (Ad) vectors and DNA electroporation (DNA-EP).
• Discussion of heterologous prime-boost immunization strategies.

Main Results:

• Genetic vaccines, including Ad vectors and DNA-EP, demonstrate promising immunogenicity for eliciting anti-TAA responses.
• Adenovirus (Ad)-based vectors have achieved immunological proof of concept in humans.
• In vivo electroporation of plasmid DNA (DNA-EP) is a repeatable technology suitable for maintaining anti-tumor immunity.

Conclusions:

• Emerging genetic cancer vaccines, particularly Ad vectors and DNA-EP, offer significant potential for cancer therapy.
• Heterologous prime-boost strategies combining different immunization modalities can induce superior immune responses compared to single-modality vaccines.
• Ad and DNA-EP heterologous prime-boost approaches show promise for enhancing anti-tumor immunity and improving cancer control.